Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02351739 · ClinicalTrials.gov registry record · Phase 2
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
A Phase 2 study, sponsored by Acerta Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT02351739 is a Phase 2 study that has completed, run by Acerta Pharma. The registered enrollment target is 78 participants.
The verdict
NCT02351739, a Phase 2 study, has completed, sponsored by Acerta Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer
Interventions
- DRUG pembrolizumab
- DRUG ACP-196 in combination with pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2015-04 |
| Est. Completion | 2018-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02351739
The ClinicalTrials.gov registry entry for NCT02351739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acerta Pharma, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab is the first listed.
NCT02351739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02351739 about?
NCT02351739 is a clinical study titled "Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer". Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Metastatic Urothelial Cancer
What is the current status of trial NCT02351739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2015-04. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02351739?
The interventions under investigation include: pembrolizumab (DRUG), ACP-196 in combination with pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02351739?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.